15 December 2025 - Top Stories

Recent Australian health and healthtech developments reveal both challenges and opportunities. A significant study involving over 10,600 Australians with Parkinson’s disease found that around 67% experience chronic pain, with women being more affected. The pain often impacts mobility, sleep, and mental health, highlighting a care gap that could be addressed through innovative healthtech solutions focused on pain management. Meanwhile, the regulatory landscape is evolving with the approval of nicotinamide mononucleotide (NMN) as an anti-ageing supplement, opening new avenues for anti-ageing therapies, though safety and efficacy questions remain.

In clinical practice, the debate around hyaluronic acid knee injections continues, with recent evidence suggesting limited benefit and increased risks. This underscores the importance of evidence-based treatments and the need for clinicians to stay informed about emerging research. On the policy front, Australia is moving towards standardising ADHD prescribing practices for GPs, aiming to improve access and consistency nationwide. Additionally, efforts to address the growing oncology workforce crisis are underway, with concerns about capacity and disparities in rural and Indigenous communities.

• Key move to standardise ADHD prescribing laws across states and territories.
• Approval of NMN introduces new anti-ageing supplement options, with regulatory oversight.
• Growing evidence questions the efficacy of hyaluronic acid injections for osteoarthritis.
• Progress in Medicare reforms continues, with over half of planned measures implemented.
• Australian oncologists face workforce shortages, risking patient outcomes.
• Legal considerations for AI scribes highlight the need for clear guidelines on data privacy and consent.
• Community engagement studies in Japan suggest pet ownership can foster social bonds, relevant for community health strategies.